Table 1.
FDA Approved Drugs | 2D Structures | Docking Score Kcal/mol | IFD kcal/mol | Glide Ligand Efficiency (SP) | Interacting Residues (SP) | Treatment (Existing usage) |
---|---|---|---|---|---|---|
Ornipressin | -10.376 | -10.15 | -0.144 | ASP760, THR591, ASP865, GLN815, SER814, CYS813, GLU811, TYR619 | Vasoconstrictor, Renal failure during decompensated liver cirrhosis [23, 24] |
|
Atosiban | -10.096 | -11.11 | -0.148 | ASP760, GLU811, SER814, TYR619, ASP833 | Inhibitor of oxytocin and vasopressin [25] | |
Lanreotide | -10.059 | -9.81 | -0.131 | ASP761, ASP760, ASN691, SER682 | Analogue of Somatostatin involved in suppressing growth hormones, glucagon, and insulin [26] | |
Argiprestocin | -9.874 | -11.68 | -0.137 | ASP761, TRP617 SER814, CYS813, GLU811 | Septic shock [27] | |
Demoxytocin | -9.689 | -8.75 | -0.142 | TRP617, TYR619, LYS621, SER682, ASP760, ASP761, GLU811 | Oxytocin analogue [28] | |
Carbetocin | -9.479 | -9.61 | -0.137 | ALA550, ARG553, THR556, ASP623, ASP760, TYR619, TRP617, TRP800 | Synthetic analogue Oxytocin, postpartum hemorrhage [29] | |
Lypressin | -9.413 | -9.61 | -0.129 | ARG624, VAL557, ARG555, ARG553, ASP760, ASP761, ALA762, GLU811, TRP617, TYR619 | Vasopressins (Lysine vasopressin), diabetes insipidus, anti-diuretic [30] |
|
Examorelin | -9.308 | -10.45 | -0.143 | GLU811, ASP760, SER814, GLN815, ARG555 | Synthetic peptide increases the plasma level of growth hormones [31, 32] | |
Colistin | -9.241 | No pose | -0.113 | ASN691, ASP684, SER682, ASP760, TRP617, ASP618, TYR619, LYS551 | Lung infection [33], Cystic fibrosis [34, 35, 36], Ventilator-associated pneumonia [37], nosocomial pneumonia [38], antibiotic against multidrug-resistant gram-negative bacterial infections [39] | |
Polymyxin B1 | -9.228 | -11.92 | -0.109 | ARG555, ASN691, ASP618, ASP761, ASP760, CYS813 | Antibiotic used against multidrug-resistant gram-negative bacterial infection [39, 40] |